{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:26Z","timestamp":1793367146056,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009396","name":"University Hospital Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejso.2026.112101","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:44:19Z","timestamp":1787849059000},"page":"112101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is complete really complete? Prognostic divergence of pathological complete response after FLOT versus CROSS in esophageal adenocarcinoma"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3925-6871","authenticated-orcid":false,"given":"Pascal","family":"Burri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Viggiani","family":"d\u2019Avalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7203-7822","authenticated-orcid":false,"given":"Dimitrios","family":"Chatziisaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9374-5703","authenticated-orcid":false,"given":"Thomas","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-8879","authenticated-orcid":false,"given":"Marcel A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6171-4427","authenticated-orcid":false,"given":"Christian A.","family":"Gutschow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.112101_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s10620-023-08126-6","article-title":"Population based time trends in the epidemiology and mortality of gastroesophageal junction and esophageal adenocarcinoma","volume":"69","author":"Agarwal","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejso.2026.112101_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejso.2026.112101_bib3","article-title":"Esophageal cancer trends in the US from 1992 to 2019 with projections to 2044 using SEER data","volume":"15","author":"Xie","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2026.112101_bib4","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112101_bib5","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112101_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN Clinical Practice Guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejso.2026.112101_bib7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jtcvs.2025.04.009","article-title":"The 2025 American Association for Thoracic Surgery (AATS) expert consensus document: surgical management of esophageal and gastroesophageal junction cancer","volume":"170","author":"Molena","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112101_bib9","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO-25-00948","article-title":"Recurrence patterns of esophageal adenocarcinoma in the phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy","volume":"43","author":"Hoeppner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib10","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO-25-01552","article-title":"Apples, oranges, and ESOPEC recurrence patterns","volume":"43","author":"Strickland","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112101_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111374","article-title":"Understanding divergent outcomes: a comparative analysis of ESOPEC and CROSS real-world studies in esophageal adenocarcinoma","volume":"52","author":"Burri","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2026.112101_bib14","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2026.112101_bib15","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-022-11700-3","article-title":"Long-term outcome after histopathological complete response with and without nodal metastases following multimodal treatment of esophageal cancer","author":"Schroeder","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib16","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.21037\/jtd.2018.04.136","article-title":"ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what\u2019s up?","volume":"10","author":"Depypere","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejso.2026.112101_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103067","article-title":"Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands","volume":"80","author":"van Laarhoven","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejso.2026.112101_bib18","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT versus FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-Positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib19","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1245\/s10434-026-19175-2","article-title":"Neoadjuvant chemoradiation versus chemotherapy for esophageal cancer: a histology-stratified update meta-analysis of randomized controlled trials","volume":"33","author":"Fleming","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110528","article-title":"The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: a meta-analysis","volume":"52","author":"Cao","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116602","article-title":"Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?","volume":"237","author":"Leite","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2026.112101_bib22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib23","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrab022","article-title":"Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer","volume":"5","author":"de Jongh","year":"2021","journal-title":"BJS Open"},{"key":"10.1016\/j.ejso.2026.112101_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2013.51.2186","article-title":"Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials","volume":"32","author":"Oppedijk","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bjs.8968","article-title":"Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer","volume":"100","author":"van Hagen","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/SLA.0000000000002352","article-title":"Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma","volume":"268","author":"Xi","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib28","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1245\/s10434-025-18676-w","article-title":"Long-term oncologic outcomes following pathologic complete response for esophageal cancer","volume":"33","author":"Sinnamon","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/0284186X.2020.1870246","article-title":"Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study","volume":"60","author":"Al-Kaabi","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib30","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/jcm9082654","article-title":"Pattern of recurrence and patient survival after perioperative chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for locally advanced esophagogastric adenocarcinoma in patients treated outside clinical trials","volume":"9","author":"Glatz","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejso.2026.112101_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO.2026.44.2_suppl.370","article-title":"Italian prospective observational RealFLOT study: four-year update","volume":"44","author":"Valle","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/cancers16071291","article-title":"Perioperative chemotherapy for gastro-esophageal or gastric cancer: anthracyclin triplets versus FLOT","volume":"16","author":"Geerts","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2026.112101_bib33","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/jcm15062367","article-title":"Prognostic impact and postoperative management following poor pathological response to perioperative FLOT in resectable gastric and GEJ adenocarcinoma: a systematic review and meta-analysis","volume":"15","author":"Massalha","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejso.2026.112101_bib34","article-title":"Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study","volume":"112","author":"Collaborative","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/SLA.0000000000005619","article-title":"An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma","volume":"276","author":"Cools-Lartigue","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1245\/s10434-025-18140-9","article-title":"Outcomes of neoadjuvant chemotherapy versus chemoradiation for esophageal adenocarcinoma: a national cancer database analysis","volume":"33","author":"Shridhar","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2026.2703","article-title":"FLOT vs CROSS among patients with pathological complete response in esophageal adenocarcinoma","author":"Alhayo","year":"2026","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2026.44.2_suppl.302","article-title":"Neoadjuvant chemoradiotherapy versus chemotherapy alone for locally advanced esophageal adenocarcinoma: a National Cancer Database analysis","volume":"44","author":"Mansoor","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2026.112101_bib40","doi-asserted-by":"crossref","first-page":"e1026","DOI":"10.1097\/SLA.0000000000005394","article-title":"Postoperative and pathological outcomes of CROSS and FLOT as neoadjuvant therapy for esophageal and junctional adenocarcinoma: an international cohort study from the oesophagogastric anastomosis audit (OGAA)","volume":"277","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/SLA.0000000000005617","article-title":"CROSS versus FLOT regimens in esophageal and esophagogastric junction adenocarcinoma: a propensity-matched comparison","volume":"276","author":"Donlon","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/SLA.0000000000006018","article-title":"Neoadjuvant chemoradiotherapy versus chemotherapy for the treatment of locally advanced esophageal adenocarcinoma in the European Multicenter ENSURE Study","volume":"278","author":"Elliott","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s13304-023-01497-5","article-title":"Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution","volume":"75","author":"Lombardi","year":"2023","journal-title":"Updates Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib44","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ejso.2017.06.003","article-title":"Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study","volume":"43","author":"Favi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2026.04.043","article-title":"Neoadjuvant chemoradiation versus perioperative chemotherapy in locally advanced resectable esophageal adenocarcinoma: a national analysis","author":"Sakowitz","year":"2026","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib46","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1200\/JCO.22.02279","article-title":"Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma","volume":"41","author":"Faron","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf157","article-title":"Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis","volume":"30","author":"Anjum","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2026.112101_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znag012","article-title":"Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma","volume":"113","author":"Okui","year":"2026","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib49","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1186\/s12885-025-14548-4","article-title":"Recurrence patterns and long-term survival of locally advanced esophageal cancer patients with pathological complete response after different neoadjuvant therapies followed by surgery","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112101_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(25)00027-0","article-title":"Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial","volume":"26","author":"van der Wilk","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/SLA.0000000000004930","article-title":"Chemoradiotherapy followed by active surveillance versus standard esophagectomy for esophageal cancer: a systematic review and individual patient data meta-analysis","volume":"275","author":"van der Wilk","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2025.5890","article-title":"Esophagectomy vs active surveillance in clinical complete responders after neoadjuvant chemoradiation","volume":"161","author":"Bondzi-Simpson","year":"2026","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17243926","article-title":"Esophagectomy versus active surveillance after complete response in locally advanced esophageal cancer: retrospective analysis","volume":"17","author":"Gur","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2026.112101_bib54","doi-asserted-by":"crossref","first-page":"TPS4185","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4185","article-title":"ESORES-Trial: surgery as needed versus surgery on principle in patients with postneoadjuvant clinical complete tumor response of esophageal cancer","volume":"42","author":"Hipp","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.2024.42.3_suppl.328","article-title":"Chemotherapy and chemoradiotherapy for adenocarcinoma of the esophagus and junction with oligometastases: results of the TNT-OES-1 trial","volume":"42","author":"van der Zijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112101_bib57","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2025.43.16_suppl.4000","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib58","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1245\/s10434-025-17264-2","article-title":"Prognostic value of tumor regression grade after chemotherapy versus chemoradiotherapy in patients undergoing neoadjuvant treatment for locally advanced esophageal adenocarcinoma","volume":"32","author":"Capovilla","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00423-023-03100-2","article-title":"Oncological recurrence following pathological complete response after neoadjuvant treatment in patients with esophageal cancer - a retrospective cohort study","volume":"408","author":"Hipp","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2026.04.014","article-title":"Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma","author":"Liu","year":"2026","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2026.112101_bib61","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","article-title":"Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling","volume":"32","author":"Ococks","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib62","article-title":"Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers","volume":"6","author":"Huffman","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib63","article-title":"Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response","volume":"8","author":"Lander","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-01069","article-title":"Targeted molecular profiling of circulating cell-free DNA in patients with gastroesophageal adenocarcinoma","volume":"10","author":"Cytryn","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib65","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","article-title":"Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study","volume":"16","author":"Zaanan","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejso.2026.112101_bib66","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.2025.43.16_suppl.4061","article-title":"Feasibility of circulating tumor DNA-based minimal residual disease (ctDNA-MRD)-guided adjuvant chemotherapy in patients with stage II-III gastric cancer (GC): an adaptive trial (MRD-GATE)","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112101_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115292","article-title":"Disease-free survival as surrogate for overall survival in esophageal cancer: an individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy","volume":"218","author":"Cabrit","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2026.112101_bib68","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1097\/JS9.0000000000003017","article-title":"Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis","volume":"111","author":"Shen","year":"2025","journal-title":"Int J Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:45:03Z","timestamp":1793364303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326007201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0748798326007201"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112101","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is complete really complete? Prognostic divergence of pathological complete response after FLOT versus CROSS in esophageal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112101"}}